Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel
BJU International · 2025
DOI: 10.1111/bju.16486 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Mohamad Abou Chakra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Gemcitabine, Deoxycytidine, Neutrophils. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCI NIH HHS, John and Carol Walter Family Foundation.
Abstract (Originalsprache)
Objectives
To investigate the role of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) in the prediction of response to sequential intravesical therapy, gemcitabine and docetaxel (Gem/Doce), given to patients with bacille Calmette–Guérin (BCG)‐ naïve high‐risk non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods A retrospective analysis was conducted on 115 patients who received intravesical Gem/Doce for high‐risk NMIBC between January 2011 and December 2021. Data were computed as the median (interquartile range [IQR]) or mean (standard deviation [ sd ]). Cox regression analysis was performed to determine if neutrophilia, NLR, platelet counts, and PLR before instillation therapy were predictive of recurrence‐free survival (RFS) and overall survival (OS). Predictive performance was estimated using Uno's C‐statistic.
Results
The median (IQR) follow‐up for the overall cohort was 23 (13–36) months. The mean ( sd ) values for NLR, PLR and platelet counts were 3.4 (2.3), 142.2 (85.5), and 225.2 (75.1) × 10 9 /L, respectively. NLR was associated with RFS, with a hazard ratio of 1.32 (95% confidence interval CI 1.19–1.46). Concordance analysis showed that NLR had a good ability to predict RFS (C‐index: 0.7, P < 0.01). The PLR and platelet count were not associated with RFS and did not predict recurrence. In terms of OS, none of these cellular inflammatory markers showed any prediction value.
Conclusion
Pre‐treatment NLR provides some predictive accuracy for RFS in high‐risk BCG‐naïve patients receiving Gem/Doce. Further prospective trials are needed to validate this finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
- Unit of Coagulation Disorders, Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland.
- Research Program Unit in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
- Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
ORCID-Profile: Riitta Lassila, Nancy El Beayni, Michael A O'Donnell
Förderung
- NCI NIH HHS
- John and Carol Walter Family Foundation
Zitieren
APA
Chakra, M. A., Lassila, R., El Beayni, N., Mott, S. L., & O'Donnell, M. A. (2025). Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel. BJU International. https://doi.org/10.1111/bju.16486
Vancouver
Chakra MA, Lassila R, El Beayni N, Mott SL, O'Donnell MA. Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel. BJU International. 2025. doi:10.1111/bju.16486
BibTeX
@article{Chakra2025,
author = {Chakra, Mohamad Abou and Lassila, Riitta and El Beayni, Nancy and Mott, Sarah L and O'Donnell, Michael A},
title = {Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel},
journal = {BJU International},
year = {2025},
doi = {10.1111/bju.16486}
}
EUVIMED